Company news
Atrium Therapeutics, Inc. news in 2024
Atrium Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
November 11, 2024
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
November 6, 2024
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
October 30, 2024
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
October 29, 2024
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
October 2, 2024
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
September 4, 2024
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
August 18, 2024
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
August 8, 2024
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skippin...
August 8, 2024
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
August 4, 2024
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
June 19, 2024
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
June 16, 2024
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
June 12, 2024
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
June 11, 2024
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
June 11, 2024
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
May 28, 2024
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
May 14, 2024
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 8, 2024
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
May 7, 2024
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
March 3, 2024
Avidity Biosciences Honors Rare Disease Day®
February 28, 2024
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
February 28, 2024
Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights
February 27, 2024
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
February 19, 2024
Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 14, 2024
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
January 4, 2024